OGN Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 май 2024 @ 23:00):

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally...

Stats
Объем за сегодня	3.20M
Средний объем	2.38M
Рыночная капитализация	5.01B
EPS	$0 ( 2024-05-02 )
Дата следующего отчета о доходах	( $0.930 ) 2024-06-04
Last Dividend	$0.280 ( 2023-11-10 )
Next Dividend	$0 ( N/A )
P/E	4.91
ATR14	$0.0210 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Arjona Ferreira Juan Camilo	Buy	108 932	Stock Option (right to buy)
2024-03-29	Arjona Ferreira Juan Camilo	Buy	26 595	Restricted Stock Units
2024-03-31	Morrissey Joseph T. Jr.	Buy	7 794	Common Stock
2024-03-31	Morrissey Joseph T. Jr.	Sell	2 328	Common Stock
2024-03-31	Morrissey Joseph T. Jr.	Buy	3 936	Common Stock

INSIDER POWER
64.91
Last 100 transactions
Buy: 2 246 661 \| Sell: 486 702

Объем Корреляция

Длинно: 0.18 (neutral)

Кратко: -0.92 (very strong negative)

Signal:(35.09) Neutral

Organon & Co. Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Organon & Co. Корреляция - Валюта/Сырье

0.43
( neutral )

0.56
( weak )

0.00
( neutral )

-0.23
( neutral )

-0.12
( neutral )

-0.63
( weak negative )

Organon & Co. Финансовые показатели

Annual	2023
Выручка:	$6.26B
Валовая прибыль:	$3.75B (59.84 %)
EPS:	$4.01

FY	2023
Выручка:	$6.26B
Валовая прибыль:	$3.75B (59.84 %)
EPS:	$4.01

FY	2022
Выручка:	$6.17B
Валовая прибыль:	$3.88B (62.84 %)
EPS:	$3.61

FY	2021
Выручка:	$6.30B
Валовая прибыль:	$3.92B (62.21 %)
EPS:	$5.33

Financial Reports:

No articles found.

Organon & Co. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Organon & Co. Dividend Information - Dividend Knight

Dividend Sustainability Score: 9.93 - good (99.26%) | Divividend Growth Potential Score: 4.34 - Stable (13.24%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.280	2021-08-20
Last Dividend	$0.280	2023-11-10
Next Dividend	$0	N/A
Payout Date	2023-12-14
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$2.80	--
Avg. Dividend % Per Year	2.08%	--
Score	4.57	--
Div. Sustainability Score	9.93
Div.Growth Potential Score	4.34
Div. Directional Score	7.13	--

Next Divdend (Est)
(2024-07-01)

$0.285 Estimate 37.78 %

Dividend Stability

0.76 Good

Dividend Score

4.57

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2021	$0.560	1.68%
2022	$1.120	3.59%
2023	$1.120	3.99%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.179	1.500	6.42	9.63	[0 - 0.5]
returnOnAssetsTTM	71.16	1.200	10.00	10.00	[0 - 0.3]
returnOnEquityTTM	-2.79	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0.261	-1.000	7.39	-7.39	[0 - 1]
currentRatioTTM	1.649	0.800	6.76	5.41	[1 - 3]
quickRatioTTM	0.834	0.800	9.80	7.84	[0.8 - 2.5]
cashRatioTTM	0.226	1.500	9.86	10.00	[0.2 - 2]
debtRatioTTM	0.733	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	0.792	1.000	-0.818	-0.818	[3 - 30]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.870	2.00	9.07	10.00	[0 - 20]
debtEquityRatioTTM	181.54	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.590	1.000	3.49	3.49	[0.2 - 0.8]
operatingProfitMarginTTM	0.0662	1.000	-0.675	-0.675	[0.1 - 0.6]
cashFlowToDebtRatioTTM	78.62	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	397.50	0.800	10.00	8.00	[0.5 - 2]
Total Score				9.93

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.93	1.000	9.50	0	[1 - 100]
returnOnEquityTTM	-2.79	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.870	2.00	9.38	10.00	[0 - 30]
dividendYielPercentageTTM	5.71	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
payoutRatioTTM	0.261	1.500	7.39	-7.39	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.145	1.000	8.88	0	[0.1 - 0.5]
Total Score				4.34

Organon & Co.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.